Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O95935

UPID:
TBX18_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O95935; A2RU13; Q7Z6U4; Q9UJI6

BACKGROUND:
The T-box transcription factor TBX18 is integral to the developmental processes of the heart, ureter, and skeletal system, acting as a transcriptional repressor. Its role is crucial for the proper formation of the sinoatrial node, a key component in the heart's electrical system, underscoring its importance in developmental biology.

THERAPEUTIC SIGNIFICANCE:
Linked to Congenital anomalies of kidney and urinary tract 2, T-box transcription factor TBX18's dysfunction is a primary cause of chronic kidney disease in children. Exploring the therapeutic potential of targeting TBX18 could lead to groundbreaking treatments for these congenital disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.